



Takeda – Israel 2025 Health Tech Pilot Program

Call for Proposals

The *Israel Innovation Authority* and *Takeda Pharmaceuticals* invite interested Israeli companies to submit applications to collaborate in pilot healthcare-related technology activities.

Takeda and the Israel Innovation Authority are seeking to advance healthcare by helping Israeli companies get the evidence and assistance they need to fine-tune their development and to enter and be successful in the -Global healthcare market.

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. With a history spanning over 240 years, Takeda is committed to bringing Better Health and a Brighter Future to people worldwide. The company focuses on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology, with targeted investments in Plasma-Derived Therapies and Vaccines. Takeda leverages its extensive scientific expertise, innovative technologies, and a collaborative approach to develop transformative treatments. By prioritizing patients, trust, reputation, and business, Takeda aims to deliver life-changing medicines and contribute to the well-being of communities globally

Takeda would serve as a real-world living laboratory for the Israeli companies to test and improve an existing process, service, or product; or to apply a new process to health care for the first time.

The goal of this collaboration is to accelerate the availability of medical innovations to the public, introduce Israeli healthcare technology to the -Global market., and advance the development and deployment of discoveries for the benefit of patients everywhere.

The **Israel Innovation Authority** provides resources to aid technology advancement for Israeli companies.



Areas Takeda focus on include but are not limited to:

Digital or mobile healthcare technology solutions, applications, and innovative medical devices (wearables) for optimizing treatment and care in the Psoriasis area.

Digital solution for decision support tool in Psoriasis.

Supported activities may include: piloting, testing (of different kinds; including in real-world conditions), validation, trials, performance verification, device iteration, product and interface customization, pre-pilot activities, R&D activities needed for the pilot, optimizing the clinical use of a given technology/product, identifying the parameters of the product/technology and potential use cases, optimizing user interfaces, etc.

What support do the Israel Innovation Authority and Takeda offer?

Successful Israeli applicant companies will receive funding from the Israel Innovation Authority. The Israel Innovation Authority can support selected companies with a grant of up to 50% of the approved Budget, according to its regulations and procedures. The Israeli companies must follow Israel Innovation Authority's rules and regulations, as described in the Hebrew website:

<https://innovationisrael.org.il/international/rnd>

When a project eventually results in sales of a product, service, or process, the financial support must be repaid in royalties to the *Israel Innovation Authority* according to its regulations. In general, royalties are paid at rates beginning at 3% of sales, depending on various criteria. Royalties are payable until 100% of the amount of the grant has been repaid with interest as provided in the applicable regulations. If the project does not result in sales, no repayment is required.

Takeda would provide assistance for the project and make it accessible through an applicable agreement with the selected Israeli companies.



Takeda may provide in-kind services, expertise, and/or use of facilities. Examples for such in-kind support can include¹:

- Matching the startup's project to the right clinician
- Explore potential partnership with HMOs
- Arrangement of first meetings, introduction to possible PIs
- Support with the contract preparation and all adjustments
- Preparing a cost-overview and support for the study planning with the PI
- Management of the Health Tech Program's milestones
- Usage of internal services, expertise, knowledge or equipment

An appropriate agreement between successful applicant companies and Takeda will need to be signed as one of the first milestones during the project initiation.

Process and Timeline

Program launch	March 3 rd 2025
Deadline for submission of Expression of Interest (EOI)	April 24 th 2025
Health centers select shortlisted companies, IIA invites shortlisted applicants to submit full application	June 9 th 2025
Deadline for full IIA online application	July 29 th 2025
IIA funding decision & project launch	October 30 th 2025

¹ Support may vary subject to the health center discretion.



Contacts

Takeda

Orna Ben Baruch

Director, Head of Patients Value and Access

Takeda Israel

Tel.: +972 54 5211427

E-Mail: Orna.Ben-Baruch@takeda.com

Natalie Shapira

Director, Head of Strategy and Operations

Takeda Israel

Tel.: +972 54 9800835

E-Mail: Natalie.Shapira@takeda.com

Israel Innovation Authority

International Collaborations Division

odelia.toledano@innovationisrael.org.il
growth@innovationisrael.org.il